Of these, five trials studied TKI/anti-VEGF (REACH, REACH-2, METIV-HCC, CELESTIAL, and JET-HCC; total of 2083 patients), and three studied immunotherapies (CheckMate-459, Journal Pre-proof 14, IMbrave150 and KEYNOTE-240; with a total of 1656 patients). The gene discussed is VEGFA; the disease is hepatocellular carcinoma.